Kura’s stock jumps on PhIb readout; FDA lifts hold on INmune Bio program; Nanobiotix’s $20M milestone
30 Jan 2024
Clinical Result
Plus, news about Iterum Therapeutics, Astria Therapeutics, Aqemia, Akebia Therapeutics, Tourmaline Bio and Vera Therapeutics:
Kura Oncology’s positive PhIb readout:
The company
is testing
its in-house menin inhibitor drug, ziftomenib, in combination with different standards of care in 20 patients with acute myeloid leukemia. All five patients receiving one form of standard of care plus ziftomenib achieved a complete response, while 8 of 15 who received a different standard of care regimen also responded to the combo. There were no differentiation syndrome events reported, Kura said. As of the Jan. 11 data cutoff, 16 of 20 patients remain in the trial. Kura’s stock
$KURA
gained about 14% on Tuesday morning. —
Max Gelman
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.